Literature DB >> 11239021

Erythropoietin modulates angiotensin II- or noradrenaline-induced Ca(2+) mobilization in cultured rat vascular smooth-muscle cells.

T Akimoto1, E Kusano, N Fujita, K Okada, O Saito, S Ono, Y Ando, S Homma, T Saito, Y Asano.   

Abstract

BACKGROUND: It has been reported that human recombinant erythropoietin (rHuEpo) modulates the sensitivity of the cardiovascular system to angiotensin II (Ang II) or noradrenaline (NA). In the present study, we explored the effect of rHuEpo on the responsiveness of Ang II- or NA-induced cytosolic free calcium ([Ca(2+)]i) mobilization in cultured rat vascular smooth-muscle cells (VSMC).
METHODS: [Ca(2+)]i concentrations in VSMC were measured by using the calcium-sensitive fluorescent dye fura-2.
RESULTS: The addition of rHuEpo (250 U/ml) alone induced elevation in [Ca(2+)]i, which remained significantly elevated above basal level for at least 60 min in the presence of extracellular Ca(2+). Pre-incubation with specific protein kinase C (PKC) inhibitor calphostin C (1 micromol/l) significantly reduced the peak and the sustained elevations of [Ca(2+)]i. Pre-treatment with rHuEpo for 60 min increased both basal [Ca(2+)]i and the changes in [Ca(2+)]i by Ang II or NA in a dose-dependent manner in the presence of extracellular Ca(2+). The synergistic effects of rHuEpo with Ang II or NA were also retained when VSMC were bathed in the Ca(2+)-free medium after the pre-incubation of rHuEpo. Conversely, they were diminished in the presence of extracellular Ca(2+) combined with intracellular Ca(2+) release inhibitor 8-(NN-diethylamino)octyl-1,3,4,5-trimethoxybenzoate (TMB-8). The synergistic effects of rHuEpo were also diminished by PKC depletion or by PKC inhibitor.
CONCLUSIONS: These observations suggest that rHuEpo has synergistic effects on Ang II- or NA-induced [Ca(2+)]i mobilization, particularly on intracellular Ca(2+) release, in VSMC. This may be a potential mechanism contributing to hypertension associated with rHuEpo therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239021     DOI: 10.1093/ndt/16.3.491

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

1.  Serum erythropoietin levels in patients with central serous chorioretinopathy.

Authors:  Burak Turgut; Nevin Ilhan; Fatma Yayla Uyar; Ulku Celiker; Tamer Demir; Suleyman Serdar Koca
Journal:  Eye Brain       Date:  2010-06-05

2.  Epidemiologic and Genetic Associations of Erythropoietin With Blood Pressure, Hypertension, and Coronary Artery Disease.

Authors:  Pengfei Sun; Nitin Kumar; Adrienne Tin; Jing Zhao; Michael R Brown; Zesen Lin; Min-Lee Yang; Qiwen Zheng; Jia Jia; Lawrence F Bielak; Bing Yu; Eric Boerwinkle; Kristina L Hunker; Josef Coresh; Y Eugene Chen; Yong Huo; Sharon L R Kardia; Rami Khoriaty; Xiang Zhou; Alanna C Morrison; Yan Zhang; Santhi K Ganesh
Journal:  Hypertension       Date:  2021-09-07       Impact factor: 10.190

Review 3.  Bench to bedside: A role for erythropoietin in sepsis.

Authors:  Andrew P Walden; J Duncan Young; Edward Sharples
Journal:  Crit Care       Date:  2010-08-06       Impact factor: 9.097

4.  Administration of a High-Dose Erythropoietin-Stimulating Agent in Hemodialysis Patients is Associated with Late Arteriovenous Fistula Failure.

Authors:  Hye Yun Jeong; Eun Jung Ko; Sang Hoon Kim; Mi Jung Lee; Hye Jeong Cho; Dong Ho Yang; So Young Lee
Journal:  Yonsei Med J       Date:  2017-07       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.